<DOC>
	<DOCNO>NCT00837343</DOCNO>
	<brief_summary>Bipolar disorder ( BD ) also name bipolar affective disorder , belong kind severe mental disorder involve mania hypomania depression episode , lifetime prevalence 1.2 - 1.6 % . The hygienic burden bipolar disorder high , disease burden lie top 10 position among population 15 - 44 year old patient concomitant relative high suicide rate ( 10 - 15 % ) mutilation rate , report World Health Organization ( WHO ) 2001 Annual Report . Drug treatment one main treatment method kind disease , dose select interfere efficacy prognosis patient . Quetiapine fumarate ( Seroquel ) dibenzothiazepine derivative , widely use world . It indications schizophrenia , bipolar mania depression approve FDA . Quetiapine fumarate use China almost 10 year , treatment schizophrenia . The indication bipolar mania approve SFDA recently . Exploration relationship dose efficacy hot spot clinical practice drug broad action spectrum wide dose range ( 200mg/d－800mg/d ) . Brain-derived neurotrophic factor ( BDNF ) play important role pathophysiology bipolar disorder . Some clinical study indicate blood BDNF level decrease depression phase bipolar disorder , blood BDNF level negative proportional severity depression ; phenomenon find , i.e . blood BDNF level decrease manic phase bipolar disorder , blood BDNF level negative proportional severity mania . Quetiapine fumarate find reduce decrease expression BDNF rat hippocampus brain mantle animal experiment , indicate quetiapine fumarate possibility potential interfering BDNF treatment . However , study comparison blood BDNF level pre post treatment bipolar disorder conduct .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Flexible Dose Quetiapine Fumarate ( Seroquel ) Switching From Other Drugs Treatment Acute Manic Patients With Bipolar Disorder</brief_title>
	<detailed_description>This multicenter , open label , 4-week study . Study subject define Chinese Han nationality patient acute mania bipolar disorder ( inpatient outpatient ) . The screen phase 7 day . The eligible patient screen phase enrol treatment phase , target dose 400-800mg/day , treatment period last 4 week . The objective evaluate efficacy quetiapine fumarate switch drug use monotherapy treatment acute mania bipolar disorder , relationship serum BDNF quetiapine fumarate .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>1 . Written inform consent submit subject legal guardian 2 . Bipolar disorder ( 296.0x , 296.4x ) diagnose Structured Clinical Interview DSMIV Axis I Disorders Patient Edition ( SCID ) , base 4th edition US Diagnostic Statistical Manual Mental Disorders ( DSMIV ) 3 . Aged 18 65 , male female , Han nationality 4 . In acute phase mania episode YMRS total score least 22 baseline . 5 . The following drug ( lithium carbonate , sodium valproate , risperidone olanzapine ) receive previous maintain treatment ( monotherapy combination therapy ) adequate dose accord label within three month mania episode . 6 . Childbearing potential female patient conduct urine pregnancy test ( HCG ) enrolment , result negative ; also willing take contraception measure study period 7 . Be able understand comply requirement study 1 . Women pregnancy lactation 2 . The duration mania episode 2 week enrollment . 3 . DSMIV Axis I Disorders except bipolar disorder ( 296.0x , 296.4x ) 4 . Patients symptoms obvious suicide ( MADRS No . 10 score ≥4 ) , selfinjured harmful others , judge investigator 5 . Known intolerance lack response quetiapine fumarate , judge investigator 6 . Patients noncompliance history judge investigator 7 . Use potent cytochrome P450 3A4 inhibitor 14 day precede randomization , include limited ketoconazole , itraconazole , fluconazole , erythromycin , clarithromycin , troleandomycin , indinavir , nelfinavir , ritonavir , fluvoxamine , saquinavir 8 . Use potent cytochrome P450 inducers 14 day precede randomization , include limited phenytoin , carbamazepine , barbiturate , rifampin , St. John 's Wort , glucocorticoids 9. longacting antipsychotic drug inject within 1 injection interval ( prolonged act injection ) randomization 10 . Use clozapine 28 day precede randomization 11 . Substance alcohol dependence accord DSMIV criterion randomization ( except complete recover , caffeine nicotine dependence ) 12 . Dependence follow drug accord DSMIV standard 4 week precede randomization : opioids , amphetamine , barbiturate , cocaine , cannabis , hallucinogens 13 . Medical condition would affect absorption , distribution , metabolism excretion study treatment . 14 . Clinical evidence relevant disease ( e.g . renal hepatic dysfunction , severe coronary heart disease , cerebrovascular disease , hepatitis acquire immunodeficiency syndrome ( AIDS ) ) 15 . Unstable condition ( e.g . hypertension , congestive heart failure , unstable angina pectoris ) opinion investigator would negatively affect study medication would affect study medication , medical history chronic body disease . 16 . Medical history seizure disorder , except febrile convulsion 17 . Persons involve study design conducting ( suitable work staff AstraZeneca study site ) 18 . Participation another clinical study within 4 week ( long time accord local requirement ) randomisation 19 . Patients diabetes mellitus ( DM ) 20 . An absolute neutrophil count ( ANC ) &lt; 1.5 x 109/L 21 . Thyroidstimulating hormone level 10 % upper limit normal range , regardless treatment hypothyroidism hyperthyroidism . 22 . Abnormal ECG clinical significance enrollment indicate abnormal function heart , judge investigator 23 . Previous enrolment present study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Bipolar disorder</keyword>
</DOC>